GADA — anti-glutamate decarboxylase antibodies, quantitative (ICL)
Detects antibodies to glutamate decarboxylase of pancreatic beta-cells. Used for autoimmune diabetes diagnosis and beta-cell destruction risk assessment.
Deviation mechanism: antibodies against glutamate decarboxylase enzyme → beta-cell destruction → reduced insulin → elevated glucose.
Biomaterial: Venous blood
Draw blood fasting (8-12 hours without food)
Exclude alcohol 24 hours before
Avoid stress and physical activity 30 minutes before
- Suspected autoimmune diabetes (type 1 or autoimmune type 2);
- early disease onset;
- rapidly progressive diabetes requiring insulin therapy;
- diabetes type differential diagnosis.
Negative — antibodies not detected.
Positive — anti-GAD antibodies detected; confirms autoimmune diabetes character.
Endocrinologist consultation recommended.
